Key Highlights

  • GLSI shares were up 23.26%, at USD 16.96, in intraday data on Tuesday, November 17, 2026; multiplying the share count by that price gives a value near USD 249 million (calculated).
  • The company announced on November 17, 2026 that the San Antonio Breast Cancer Symposium accepted two abstracts and two matching posters; the meeting runs December 8 to 11, 2026, and the posters are set for December 9.
  • The company held USD 8.88 million of cash on June 30, 2026, having lost USD 9.61 million over six months, and the quarterly filing includes going-concern language.
  • First-half at-the-market sales brought in USD 9.34 million net on 379,762 shares at an average of USD 25.36, far above where the stock trades now.

Symposium Acceptance Arrives Alongside the Rally

On November 17, 2026, Greenwich LifeSciences (NASDAQ:GLSI) said that two abstracts, plus two corresponding posters, were accepted at the San Antonio Breast Cancer Symposium. The FLAMINGO-01 Steering Committee authored both posters, which are slated for December 9, 2026 in the ongoing-trial and late-breaking sessions. Abstract titles were not provided and the release reported no fresh trial data. No further release or filing explaining the move turned up, so the match in timing is a coincidence of dates, not a stated cause. The 23.26% gain from the screener is the figure of record for intraday trading.

A Clinical-Stage Company Built Around FLAMINGO-01

Based in Stafford, Texas, Greenwich LifeSciences is a clinical-stage biopharmaceutical company. Its lead candidate, GLSI-100, is an immunotherapy that uses GP2, a 9-amino-acid fragment of the HER2 protein, with the goal of preventing breast cancer recurrence. Fast Track Designation covers its Phase III trial, FLAMINGO-01. The latest quarterly filing described an expansion into Europe and plans for up to 150 sites worldwide, but gave no enrolment figure. The company notes that roughly 75% of breast cancers express HER2 at low, intermediate or high levels, which defines the potential patient pool. Late-stage oncology trials cost a great deal and results are years off, and Greenwich LifeSciences (NASDAQ:GLSI) has no product revenue.

Going-Concern Language and At-the-Market Sales Shape the Risk

Equity raises matter because of the balance sheet. Over the six months to June 30, 2026, the net loss was USD 9.61 million, split between USD 8.77 million of Research and Development and USD 0.98 million of general and administrative expense. Cash of USD 8.88 million compares with USD 6.18 million at December 31, 2025, an increase only because at-the-market sales added USD 9.34 million net. The filing says conditions raise substantial doubt about continuing as a Going Concern for a year. As of July 24, 2026 there were 14,678,208 shares outstanding, so further sales would dilute holders, and a rally can make them easier, a point that cuts against the move at Greenwich LifeSciences (NASDAQ:GLSI).

Where Things Stand

The only dated company news found is a conference announcement, so the jump looks like a response to visibility, not to data. After the 23.26% gain, Greenwich LifeSciences (NASDAQ:GLSI) sits about 33% below the USD 25.36 average price of its first-half share sales (calculated). Next up are the December 9, 2026 posters, and the move would be tested by an enrolment update, fresh financing or a third-quarter filing. For now, the shares reflect hopes for a trial that has not yet reported results.